Aravive to Participate in Upcoming Virtual Investor Conferences in March
02 March 2021 - 11:00PM
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company
developing transformative therapeutics, today announced that the
Company will present and conduct one-on-one meetings at the
following two virtual investor conferences in March:
- H.C. Wainwright Global Life Sciences Conference taking place
March 9-10, 2021. Aravive’s presentation will be available for
viewing on March 9, 2021.
- Oppenheimer 31st Annual Healthcare Conference on Thursday,
March 18, 2021, at 8:00 a.m. ET
Live webcasts and audio archives of the presentations will be
available at http://ir.aravive.com. Archived replays of the
webcasts will be available for 90 days following the
presentations.
About AraviveAravive, Inc. is a
clinical-stage oncology company developing transformative
therapeutics designed to halt the progression of life-threatening
diseases. Aravive is based in Houston, Texas and received a Product
Development Award from the Cancer Prevention & Research
Institute of Texas (CPRIT) in 2016. Aravive’s lead product
candidate, AVB-500, is an ultra-high affinity decoy protein that
targets the GAS6-AXL signaling pathway associated with tumor cell
growth. Aravive successfully completed a Phase 1b trial of AVB-500
in platinum resistant ovarian cancer and plans to initiate a
pivotal Phase 3 trial of AVB-500 at a dose of 15 mg/kg. While the
Phase 1b trial of AVB-500 in platinum resistant ovarian cancer was
a safety trial and not powered to demonstrate efficacy, all 5
patients in the 15 mg/kg cohort experienced clinical benefit, with
1 complete response, 2 partial responses, and 2 stable disease. The
Company has initiated and is recruiting for its Phase 1b/2 trial in
patients with clear cell renal cell carcinoma.
Contacts:Media:Sheryl Seapy,
W2Osseapy@w2ogroup.com(949) 903-4750
Investors:Luke Heagle, W2O lheagle@w2ogroup.com (910)
726-1372
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Apr 2024 to May 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From May 2023 to May 2024